Elevation Point Wealth Partners LLC Invests $6.18 Million in Thermo Fisher Scientific Inc. $TMO

Posted by Francis Steltz on Aug 23rd, 2026

Elevation Point Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 12,323 shares of the medical research company’s stock, valued at approximately $6,184,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after acquiring an additional 288,296 shares during the last quarter. J. Stern & Co. LLP boosted its position in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $15,501,867,000. State Street Corp increased its position in Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Finally, Capital World Investors raised its stake in Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after purchasing an additional 718,669 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 63,493 shares of company stock valued at $37,657,681. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Piper Sandler lifted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Finally, Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

View Our Latest Stock Report on TMO

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $629.02 on Friday. The firm has a 50-day simple moving average of $542.53 and a two-hundred day simple moving average of $509.70. The stock has a market cap of $232.58 billion, a PE ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the prior year, the business posted $4.28 EPS. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.